
    
      Eligible participants will undergo baseline assessments at enrollment. Study participants
      will receive a one-time administration of 68GaDOTATATE and undergo a PET/CT imaging study.
      Scans will be performed with "negative" oral contrast (e.g. Volumenâ„¢ or equivalent), as many
      NETs involve the GI tract.
    
  